3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
2
Unknown
1
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Other solid neoplasm
1
NET
1
Head & Neck
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Breast
1
Conditions
Colorectal Neoplasms
15
Carcinoma, Hepatocellular
8
Neoplasm Metastasis
3
Rectal Neoplasms
2
Melanoma
2
Cholangiocarcinoma
2
Advanced Colorectal Cancer
2
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thyroid Neoplasms
1
Tertiary Lymphoid Structures
1
TAS 102
1
Stomach Neoplasms
1
Sarcoma
1
Mesothelioma, Malignant
1
Liver Neoplasms
1
Gastrointestinal Stromal Tumors
1
Gastro-enteropancreatic neuroendocrine tumor
1
Fatigue
1
Colorectal Cancer Metastatic
1
Colorectal Cancer Liver Metastases
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Biliary Tract Neoplasms
1
Asian Colorectal Cancer Patients
1
Advanced Colorectal Carcinoma
1
Advanced Biliary Systemic Tumours That Has Failed at Least One Prior Systemic Therapy
1
Interventions
Carboplatin
84
Cisplatin
79
Pemetrexed
72
Docetaxel
62
Drug Therapy
44
Gemcitabine
43
Erlotinib Hydrochloride
42
Gefitinib
38
Radiotherapy
36
Paclitaxel
36
pembrolizumab
31
Bevacizumab
29
icotinib
28
osimertinib
27
anlotinib
26
Nivolumab
26
camrelizumab
23
Vinorelbine
23
Radiosurgery
20
aumolertinib
18
atezolizumab
17
sintilimab
16
apatinib
16
Endostatins
16
endostar protein
15
durvalumab
14
Surgical Procedures, Operative
13
Immunotherapy
13
Immune Checkpoint Inhibitors
12
Blood Specimen Collection
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Carcinoma, Non-Small-Cell Lung
×
regorafenib
×
Clear all
NCT03475953
2023-03-03
REGOMUNE
Institut Bergonié
Phase 1/2
Unknown
747 enrolled